55 reports of this reaction
2.5% of all AVOBENZONE, OCTISALATE, AND OCTOCRYLENE reports
#11 most reported adverse reaction
RASH is the #11 most commonly reported adverse reaction for AVOBENZONE, OCTISALATE, AND OCTOCRYLENE, manufactured by Alchemee, LLC. There are 55 FDA adverse event reports linking AVOBENZONE, OCTISALATE, AND OCTOCRYLENE to RASH. This represents approximately 2.5% of all 2,163 adverse event reports for this drug.
Patients taking AVOBENZONE, OCTISALATE, AND OCTOCRYLENE who experience rash should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RASH is a less commonly reported adverse event for AVOBENZONE, OCTISALATE, AND OCTOCRYLENE, but still significant enough to appear in the safety profile.
In addition to rash, the following adverse reactions have been reported for AVOBENZONE, OCTISALATE, AND OCTOCRYLENE:
The following drugs have also been linked to rash in FDA adverse event reports:
RASH has been reported as an adverse event in 55 FDA reports for AVOBENZONE, OCTISALATE, AND OCTOCRYLENE. This does not prove causation, but indicates an association observed in post-market surveillance data.
RASH accounts for approximately 2.5% of all adverse event reports for AVOBENZONE, OCTISALATE, AND OCTOCRYLENE, making it a notable side effect.
If you experience rash while taking AVOBENZONE, OCTISALATE, AND OCTOCRYLENE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.